Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study

DREAMM-2 (NCT03525678) is an ongoing global, open-label, phase 2 study of single-agent belantamab mafodotin (belamaf; GSK2857916), a B-cell maturation antigen-targeting antibody-drug conjugate, in a frozen-liquid presentation in patients with relapsed/refractory multiple myeloma (RRMM). Alongside th...

Descripción completa

Detalles Bibliográficos
Autores principales: Richardson, Paul G., Lee, Hans C., Abdallah, Al-Ola, Cohen, Adam D., Kapoor, Prashant, Voorhees, Peter M., Hoos, Axel, Wang, Karrie, Baron, January, Piontek, Trisha, Byrne, Julie, Richmond, Scott, Jewell, Roxanne C., Opalinska, Joanna, Gupta, Ira, Lonial, Sagar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584571/
https://www.ncbi.nlm.nih.gov/pubmed/33097687
http://dx.doi.org/10.1038/s41408-020-00369-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584571/
https://www.ncbi.nlm.nih.gov/pubmed/33097687
http://dx.doi.org/10.1038/s41408-020-00369-0

Ejemplares similares